PMID- 30192155
OWN - NLM
STAT- MEDLINE
DCOM- 20190909
LR  - 20190909
IS  - 2042-6313 (Electronic)
IS  - 2042-6305 (Linking)
VI  - 7
IP  - 9
DP  - 2018 Sep
TI  - Costs associated with adverse events for systemic therapies in metastatic 
      melanoma.
PG  - 867-879
LID - 10.2217/cer-2018-0022 [doi]
AB  - AIM: To determine the costs of adverse events (AEs) associated with current 
      metastatic melanoma (MM) therapies. MATERIALS & METHODS: Two retrospective cohort 
      studies were independently conducted using the PharMetrics and MarketScan 
      databases. Included patients were aged >/=18 years, and had >/=1 MM diagnosis and >/=1 
      claim for systemic therapy from 2004 to 2015. RESULTS: A total of 1654 and 1329 
      patients were identified in PharMetrics and MarketScan, respectively. The 
      corresponding adjusted 30-day incremental costs of AEs by category were highest 
      for CNS/psychiatric (US$21,277 and $18,739), gastrointestinal ($18,534 and 
      $15,648), respiratory ($17,338 and $17,064), cardiovascular ($16,083 and 
      $15,430), hematological/lymphatic ($14,997 and $15,538) and metabolic/nutritional 
      AEs ($12,340 and $17,251). CONCLUSION: The costs of AEs associated with systemic 
      therapies for MM are substantial.
FAU - Fu, Alex Z
AU  - Fu AZ
AD  - Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 
      Washington, DC 20007, USA.
FAU - Li, Zhiyi
AU  - Li Z
AD  - Asclepius Analytics LLC, New York, NY 10004, USA.
FAU - Tang, Jackson
AU  - Tang J
AD  - Asclepius Analytics LLC, New York, NY 10004, USA.
FAU - Mahmood, Syed
AU  - Mahmood S
AD  - Jacobi Medical Center & North Central Bronx Hospital, Bronx, NY 10461, USA.
FAU - Whisman, Tyler
AU  - Whisman T
AD  - Novartis Oncology, Novartis Pharmaceuticals Corporation, East Hanover, NJ 
      07936-1080, USA.
FAU - Qiu, Ying
AU  - Qiu Y
AD  - Worldwide Health Economics and Outcomes Research, Bristol-Myers Squibb 
      Corporation, Princeton Pike, NJ 08648, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180907
PL  - England
TA  - J Comp Eff Res
JT  - Journal of comparative effectiveness research
JID - 101577308
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antineoplastic Agents/*adverse effects/economics
MH  - Databases, Factual
MH  - Drug Costs
MH  - Female
MH  - Health Care Costs
MH  - Humans
MH  - Male
MH  - Melanoma/drug therapy/*economics
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Skin Neoplasms/drug therapy/*economics
MH  - Treatment Outcome
OTO - NOTNLM
OT  - adverse events
OT  - chemotherapy
OT  - cost
OT  - immunotherapy
OT  - metastatic melanoma
OT  - targeted therapy
EDAT- 2018/09/08 06:00
MHDA- 2019/09/10 06:00
CRDT- 2018/09/08 06:00
PHST- 2018/09/08 06:00 [pubmed]
PHST- 2019/09/10 06:00 [medline]
PHST- 2018/09/08 06:00 [entrez]
AID - 10.2217/cer-2018-0022 [doi]
PST - ppublish
SO  - J Comp Eff Res. 2018 Sep;7(9):867-879. doi: 10.2217/cer-2018-0022. Epub 2018 Sep 
      7.